---
title: "Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Autologous cellular immunotherapy"
description: "Formulary evidence on Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Autologous cellular immunotherapy. Topics: FDA-approved indication and dosing, Asymptomatic or minimally symptomatic disease: trial population, Asymptomatic or minimally symptomatic disease: overall survival versus control, Time to disease progression, and 1 further topic. 5 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description/autologous-cellular-immunotherapy"
published: "2026-11-15T21:45:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Autologous cellular immunotherapy

<a id="heading-2.2.2.1.7"></a>

## 2.2.2.1.7 Autologous Cellular Immunotherapy

<a id="topic-2.2.2.1.7-1"></a>

### FDA-approved indication and dosing

> “PROVENGE is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.”
> “Administer 3 doses at approximately 2-week intervals.”
> “Each dose of PROVENGE requires a standard leukapheresis procedure approximately 3 days prior to the infusion.”

Source: [Provenge prescribing information](https://www.fda.gov/media/78511/download)

<a id="topic-2.2.2.1.7-2"></a>

### Asymptomatic or minimally symptomatic disease: trial population

> “Exclusion criteria included visceral (liver, lung, or brain) metastases, moderate to severe prostate cancer-related pain, and use of narcotics for cancer-related pain.”
> “Forty-eight percent of patients were receiving bisphosphonates and 18% had received prior chemotherapy, including docetaxel.”

Source: [Provenge prescribing information](https://www.fda.gov/media/78511/download)

<a id="topic-2.2.2.1.7-3"></a>

### Asymptomatic or minimally symptomatic disease: overall survival versus control

| Study | Sipuleucel-T, median months (95% CI) | Control, median months (95% CI) | Hazard ratio | Hazard ratio 95% CI |
| --- | --- | --- | --- | --- |
| Study 1 | “25.8 (22.8, 27.7)” | “21.7 (17.7, 23.8)” | “0.775” | “(0.614, 0.979)” |

Source: [Provenge prescribing information](https://www.fda.gov/media/78511/download)

> “After a median follow-up of 34.1 months, the overall mortality was 61.6% in the sipuleucel-T group versus 70.8% in the placebo group (HRdeath, 0.78; 95% CI, 0.61–0.98;”
> “However, the improved survival was not accompanied by measurable antitumor effects.”

Source: [National Cancer Institute Prostate Cancer Treatment PDQ](https://www.cancer.gov/types/prostate/hp/prostate-treatment-pdq)

<a id="topic-2.2.2.1.7-4"></a>

### Time to disease progression

> “Analyses of time to disease progression did not meet statistical significance in any Phase 3 study of PROVENGE.”

Source: [Provenge prescribing information](https://www.fda.gov/media/78511/download)

<a id="topic-2.2.2.1.7-5"></a>

### Acute infusion reactions

> “In controlled clinical trials, severe (Grade 3) acute infusion reactions were reported in 3.5% of patients in the PROVENGE group.”

Source: [Provenge prescribing information](https://www.fda.gov/media/78511/download)

Additional sources: [Kantoff et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20818862/)

## Related pages
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Terms and abbreviations](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations.md)
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Product information and disease description](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Clinical evidence](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic information and modeling report](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: References](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references.md)
